Treatment of Severe Mitral Stenosis with Moderate Aortic Regurgitation
In patients with severe mitral stenosis and moderate aortic regurgitation, percutaneous mitral commissurotomy (PMC) should be performed to address the severe mitral stenosis while deferring intervention on the moderate aortic regurgitation, which can be monitored and addressed surgically later if it progresses to severe. 1
Rationale and Treatment Algorithm
The 2017 ESC/EACTS Guidelines explicitly address this clinical scenario and provide clear direction: when severe mitral stenosis coexists with moderate aortic valve disease, PMC can be performed to postpone the surgical treatment of both valves 1. This recommendation is based on the principle that the severe lesion (mitral stenosis) drives symptoms and outcomes, while the moderate lesion (aortic regurgitation) does not yet meet intervention thresholds.
Step-by-Step Management Approach
1. Assess Suitability for PMC:
- Evaluate mitral valve anatomy for favorable characteristics (pliable leaflets, minimal calcification, minimal subvalvular disease, absence of left atrial thrombus)
- If anatomy is favorable and patient is symptomatic: PMC is indicated (Class I, Level B) 1
- If patient has contraindication or high surgical risk: PMC is still indicated (Class I, Level C) 1
2. If PMC is Not Suitable:
- Mitral valve surgery is indicated in symptomatic patients who are not suitable for PMC (Class I, Level C) 1
- In this scenario with moderate AR, combined surgical intervention on both valves becomes the preferred approach when PMC anatomy is unfavorable
3. Management of the Moderate Aortic Regurgitation:
- Moderate AR does not meet criteria for intervention on its own
- The AR should be monitored with serial echocardiography
- Intervention for AR is only indicated when it becomes severe AND either: symptomatic, or causes LV dysfunction (LVEF ≤50%), or patient requires other cardiac surgery 1
Critical Clinical Nuances
Why PMC First is the Optimal Strategy:
The guideline recommendation to use PMC to "postpone surgical treatment of both valves" reflects several important clinical realities:
- Hemodynamic priority: Severe MS causes more immediate morbidity through pulmonary hypertension, atrial fibrillation, and heart failure symptoms than moderate AR
- Procedural risk stratification: PMC is lower risk than double-valve surgery, allowing you to address the life-limiting lesion while avoiding the morbidity of cardiopulmonary bypass
- Natural history: Moderate AR may remain stable for years and not progress to require intervention
- Surgical timing: If AR progresses to severe later, you can perform isolated aortic valve surgery at that time with acceptable outcomes
Common Pitfalls to Avoid
1. Don't Underestimate MS Severity Due to Coexisting AR:
- The presence of AR can reduce forward flow across the mitral valve, potentially underestimating the true severity of MS
- Ensure valve area calculation is accurate (≤1.5 cm² for clinically significant MS) 1
2. Don't Rush to Combined Surgery in Favorable PMC Candidates:
- The evidence clearly supports PMC as first-line when anatomy is suitable 1
- Combined surgery exposes the patient to higher operative mortality and morbidity when one lesion is only moderate
3. Don't Ignore Contraindications to PMC:
- Left atrial thrombus (absolute contraindication)
- More than mild mitral regurgitation (relative contraindication)
- Severe or bicommissural calcification
- Absence of commissural fusion
4. Recognize When Surgery on Both Valves is Actually Needed:
- If MS anatomy is unfavorable for PMC AND patient is symptomatic, then combined mitral and aortic surgery should be considered rather than attempting suboptimal PMC
- The guideline notes that when severe MS combines with severe aortic valve disease, surgery is preferable 1; by extension, if PMC is not feasible, surgical correction of both lesions may be warranted even with moderate AR
Heart Team Evaluation
All patients with multivalvular disease require comprehensive evaluation by a multidisciplinary Heart Team (Class I, Level C) 1. This is particularly important in this scenario to:
- Determine PMC feasibility and predicted success
- Assess surgical risk if PMC is not suitable
- Decide timing of any future aortic valve intervention
- Evaluate for coronary artery disease (coronary angiography is indicated before valve surgery in patients with cardiovascular risk factors) 1
Follow-up Strategy After PMC
If PMC is successful:
- Yearly clinical and echocardiographic follow-up for the mitral valve 1
- Serial monitoring of the aortic regurgitation (typically every 1-2 years if stable and moderate)
- Watch for progression of AR to severe, which would trigger surgical evaluation
- If PMC is unsuccessful, surgery should be considered early unless definite contraindications exist 1